Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.

@article{Crespo2007PeginterferonAP,
  title={Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.},
  author={Marta Crespo and S{\'i}lvia Sauleda and Juan I. Esteban and {\'A}lvaro Ju{\'a}rez and Esteban Ribera and Ada Luz Andreu and Vicenç Falc{\'o} and Josep Quer and Inma Oca{\~n}a and Isaac Ruiz and Mar{\'i}a Asunci{\'o}n But{\'i} and Albert Pahissa and Rafael Esteban and Jaime Guardia},
  journal={Journal of viral hepatitis},
  year={2007},
  volume={14 4},
  pages={228-38}
}
Treatment of chronic hepatitis C in human immunodeficiency virus (HIV)-infected patients is associated with low response rates and high incidence of side effects. One hundred twenty-one hepatitis C virus (HCV)-HIV-coinfected patients were randomized to receive interferon alpha-2b (3 MU thrice weekly; n = 61) or peginterferon alpha-2b (1.5 microg/kg/week; n = 60), plus ribavirin (800 mg daily), for 24 (genotype 2 or 3) or 48 weeks (genotype 1 or 4). We assessed early virological response at 4, 8… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…